|
See related Keppra information |
|
|
|
Manufacturer |
GlaxoSmithKline |
|
Distributor |
Olic |
|
Contents |
Levetiracetam |
|
Indications |
Monotherapy of partial onset seizures w/ or w/o secondary generalisation in patients from 16 yr w/ newly diagnosed epilepsy. Adjunctive treatment of: Partial onset seizures in adult & childn from 4 yr w/ epilepsy; myoclonic seizures in adult & adolescent from 12 yr w/ juvenile myoclonic epilepsy; primary generalised tonic-clonic seizures in adult & adolescent from 6 yr w/ idiopathic generalised epilepsy.
Click to view Keppra detailed prescribing infomation |
|
Dosage |
Monotherapy Adult & adolescent from 16 yr Initially 250 mg bid, increased to 500 mg bid after 2 wk. Max: 1,500 mg bid. Add-on therapy Adult ≥18 yr & adolescent 12-17 yr of ≥50 kg Initially 500 mg bid. May be increased up to 1,500 mg bid. Dose titration can be made in steps of 500 mg bid at intervals of 2-4 wk. Childn 4-11 yr & adolescent 12-17 yr of <50 kg Initially 10 mg/kg bid. May be increased up to 30 mg/kg bid. Dose titration can be made in steps of 10 mg/kg bid every 2 wk. Administer Keppra vial as 15-min IV infusion.
Click to view Keppra detailed prescribing infomation |
|
Overdosage |
View Keppra overdosage for action to be taken in the event of an overdose. |
|
Administration |
May be taken with or without food |
|
Contraindications |
Hypersensitivity to pyrrolidone derivatives.
Click to view Keppra detailed prescribing infomation |
|
Special Precautions |
Avoid abrupt w/drawal. Renal & hepatic impairment. Elderly. Symptoms of depression &/or suicidal ideation. May impair ability to drive or operate machinery. Pregnancy & lactation. Childn <4 yr.
Click to view Keppra detailed prescribing infomation |
|
Adverse Drug Reactions |
Dizziness, somnolence, headache, postural dizziness, asthenia/fatigue, amnesia, ataxia, convulsion, hyperkinesia, tremor, balance disorder, disturbance in attention, memory impairment, agitation, depression, emotional lability/mood swings, hostility/aggression, insomnia, nervousness/irritability, personality disorders, abnormal thinking, abdominal pain, diarrhoea, dyspepsia, nausea, vomiting, anorexia, wt increase, vertigo, diplopia, blurred vision, myalgia, accidental injury, infection, nasopharyngitis, increased cough, rash, eczema, pruritus, thrombocytopenia.
View ADR Monitoring Form |
|
Drug Interactions |
Higher risk of anorexia when co-administered w/ topiramate.
View more drug interactions with Keppra |
|
Pregnancy Category (US FDA) |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. |
|
Caution For Usage |
For caution against possible variation of physical aspect of medicine... click to view Keppra detailed prescribing infomation |
|
Storage |
View Keppra storage conditions for details to ensure optimal shelf-life. |
|
Description |
View Keppra description for details of the chemical structure and excipients (inactive components). |
|
Mechanism of Action |
View Keppra mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
